Literature DB >> 2938058

A simultaneous comparison of fentanyl's analgesic effects on experimental and clinical pain.

Donald D Price1, Stephen W Harkins, Amir Rafii, Catherine Price.   

Abstract

Intravenous administration of 0.8 microgram/kg and 1.1 micrograms/kg fentanyl in low back pain patients reduced both sensory intensity and unpleasantness visual analogue scale (VAS) responses to experimental pain evoked by graded 5-sec nociceptive temperature stimuli (45-51 degrees C) as well as VAS-sensory and VAS-affective responses to clinical pain. Fentanyl produced similar decreases in VAS-sensory responses to experimental and clinical pain. Fentanyl produced nearly equal reductions in VAS-sensory and VAS-affective responses to experimental pain but greater reductions in clinical pain VAS-affective as compared to clinical pain VAS-sensory responses. This interaction of type of pain (experimental versus clinical) and pain dimension (sensory versus affective) results from either a steeper sensory intensity-unpleasantness relationship for clinical pain as compared to experimental pain or additional selective influences of opiates on affective factors uniquely related to clinical pain. These results indicate that low to moderate doses of opiates reduce both sensory and affective dimensions of pain and strongly suggest that changes in pain affect occur mainly as a direct consequence of reductions in pain sensation intensity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938058     DOI: 10.1016/0304-3959(86)90042-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  10 in total

1.  Psychophysical features of the transition from pure heat perception to heat pain perception.

Authors:  S Lautenbacher; A Möltner; F Strain
Journal:  Percept Psychophys       Date:  1992-12

2.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

3.  Sensory and affective aspects of pain perception: is medial thalamus restricted to emotional issues?

Authors:  M C Bushnell; G H Duncan
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  The sensory and affective components of pain: are they differentially modifiable dimensions or inseparable aspects of a unitary experience? A systematic review.

Authors:  K Talbot; V J Madden; S L Jones; G L Moseley
Journal:  Br J Anaesth       Date:  2019-05-01       Impact factor: 9.166

5.  Effect of sedation on pain perception.

Authors:  Michael A Frölich; Kui Zhang; Timothy J Ness
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

6.  Do past pain events systematically impact pain ratings of healthy subjects or fibromyalgia patients?

Authors:  Roland Staud; Michael E Robinson; Donald D Price
Journal:  J Pain       Date:  2009-09-26       Impact factor: 5.820

7.  Acute tryptophan depletion blocks morphine analgesia in the cold-pressor test in humans.

Authors:  F V Abbott; P Etienne; K B Franklin; M J Morgan; M J Sewitch; S N Young
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Pain scores are not predictive of pain medication utilization.

Authors:  Suzanne Galloway; Maryann Chimhanda; Jayme Sloan; Charles Anderson; James Sinacore; Linda Brubaker
Journal:  Pain Res Treat       Date:  2011-10-11

9.  Concussion/mild traumatic brain injury-related chronic pain in males and females: A diagnostic modelling study.

Authors:  Tatyana Mollayeva; J David Cassidy; Colin M Shapiro; Shirin Mollayeva; Angela Colantonio
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

10.  Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study.

Authors:  Mari Fihlman; E Karru; P Varpe; H Huhtinen; N Hagelberg; T I Saari; K T Olkkola
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.